Olaparib, a highly selective potent poly(ADP‐ribose) polymerase (PARP) inhibitor, that inhibits base excision repair and single‐strand DNA break (SSB) repair, has recently been approved for therapy of ovarian and breast cancer 16, 17, 18. Here, PARP1 is linked to breast carcinoma.